Searchable abstracts of presentations at key conferences on calcified tissues
Previous issue | Volume 3 | ECTS2014 | Next issue

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

Card image cap
European Calcified Tissue Society Annual Congress, 17 - 20 May 2014; Prague, Czech Republic

Poster Presentations

Osteoporosis: treatment

Contribution of circulating sclerostin and estradiol for inadequate response to bisphosphonate therapy in women with postmenopausal osteoporosis
1RETICEF, Instituto de Salud Carlos III, Madrid, Spain; 2Bone Metabolic Unit, Endocrinology Division (RETICEF), Hospital Universitario San Cecilio, Granada, Spain; 3Department of Internal Medicine, Hospital del Mar-IMIM-UAB, Barcelona, Spain; 4Department of Internal Medicine, Hospital Universitario Marqués Valdecilla, Santander, Spain; 5Osteoporosis Research Group, Universidad de Las Palmas de Gran Canaria, LasPalmas de Gran Canaria, Spain; 6Department of Internal Medicine, Fundación Jiménez Díaz, Madrid, Spain; 7Department of Internal Medicine, Hospital Universitario Río Ortega, Valladolid, Spain; 8Department of Internal Medicine, Hospital Virgen Macarena, Sevilla, Spain; 9Department of Reumatology, Hospital La Paz, Madrid, Spain; 10Department of Endocrinology, Hospital Universitario Quirón, Madrid, Spain; 11CETIR Medical Center, Barcelona, Spain; 12Trabeculae, Ourense, Spain.
ba0003pp297
Investigating effects of novel conjugate drugs for the treatment of osteoporosis
1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; 2Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; 3Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; 4Department of Chemistry, Simon Fraser University, Burnacy, British Columbia, Canada.
ba0003pp298
Association between allopurinol use and hip fracture in older patients discharged from rehabilitation
1University of Dundee, Dundee, UK; 2Scottish Collaboration for Public Health Research and Policy, Edinburgh, UK.
ba0003pp299
Effect of gastrointestinal events on treatment patterns, discontinuation, resource utilization, and cost in osteoporosis: an analysis using danish health registries
1KORA – National Institute for Municipalities’ and Regions’ Analysis
and Research, Copenhagen, Denmark; 2MSD Denmark ApS, Ballerup, Denmark; 3Clinical Institute, Aalborg University, Aalborg, Denmark; 4iTracks, Arhus, Denmark; 5Merck & Co., Whitehouse Station,
New Jersey, USA.
ba0003pp301
Comparison of osteosarcoma incidence between abaloparatide (BA058) and PTH (1--34) in long term rat studies
1Radius Health, Cambridge, Massachusetts, USA; 2Charles River
Laboratories Preclinical Services, Montreal, Quebec, Canada.
ba0003pp302
Gastrointestinal issues and osteoporosis treatment: the medication use patterns, treatment satisfaction, and inadequate control of osteoporosis study (MUSIC-OS)
1St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; 2Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy; 3Department of Rheumatology, University Hospital of Lille, Lille, France; 4Bridge Medical Center, Crawley, West Sussex, UK; 5Department of Rheumatology, Maastricht University, Maastricht, The Netherlands; 6Departments of Internal Medicine and Geriatrics, Gothenburg University, Göteborg, Sweden; 7Biomedical Research Institute, University Hasselt, Diepenbeek, Belgium; 8Merck & Co., Inc., Whitehouse Station, New Jersey, USA.
ba0003pp303
Effect of daily intake of milk enriched with a high dose of vitamin D in healthy postmenopausal women: preliminary results from a randomized, controlled and double-blind nutritional trial (The EFICALCIO study)
1Bone Metabolic Unit (RETICEF), Endocrinology Division, Hospital Universitario San Cecilio, Instituto de Investigación de Granada, Granada, Spain; 2Endocrinology Unit, Hospital General Universitario Rafael Mendez, Lorca, Murcia, Spain; 3Endocrinology, Hospital Comarcal del Noroeste, Caravaca de la Cruz, Murcia, Spain; 4Palacios Institute of Women’s Health, Madrid, Spain; 5Department of Obstetrics and Gynecology, University of Granada, Granada, Spain; 6Nutrition Department, Biosearch S.A, Granada, Spain.
ba0003pp307
Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women
1Merck & Co., Inc., Whitehouse Station, New Jersey, USA; 2Maccabi Healthcare Services, Tel Aviv, Israel; 3Technion Faculty of Medicine, Haifa, Israel; 4MSD Israel, Petah Tikva, Israel.
ba0003pp308
Treatment of severe vertebral osteoporosis with teriparatide or 1--84-PTH: results from a Danish Database Initiative
1Hvidovre Hospital, Hvidovre, Denmark; 2Aarhus Universitetshospital, THG, Aarhus, Denmark; 3Nordsjaellands Hospital, Hilleroed, Denmark; 4Odense University Hospital, Odense, Denmark; 5Glostrup Hospital, Glostrup, Denmark; 6Regionshospitalet Horsens, Horsens, Denmark; 7Herlev Hospital, Herlev, Denmark; 8Gentofte Hospital, Gentofte, Denmark; 9Svendborg Sygehus, Svendborg, Denmark; 10Vejle Sygehus, Vejle, Denmark; 11Holbaek Sygehus, Holbaek, Denmark; 12Silkeborg Sygehus, Silkeborg, Denmark; 13Frederiksberg Hospital, Frederiksberg, Denmark; 14Aarhus Universitetshospital, PGO, Aarhus, Denmark; 15Amager Hospital, København, Denmark; 16Regionshospitalet Viborg, Viborg, Denmark; 17Gigthospitalet Graasten, Graasten, Denmark; 18Speciallægeklinikken, Aalborg, Denmark.
ba0003pp309
Risk factors for the development of chronic back pain after percutaneous vertebroplasty vs conventional treatment
1Rheumatology Department, Hospital Clinic, Barcelona, Spain;
2Neurointerventional Department, Hospital Clinic, Barcelona, Spain; 3Public Health Department, University of Barcelona, Barcelona, Spain; 4CIBERehd, Barcelona, Spain.
ba0003pp310
Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania Region Database
1Department of Medical and Surgical Specialties and Dentistry, Second University of Naples, Naples, Campania, Italy; 2CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Campania, Italy.
ba0003pp311
Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis
Research Center for obstetrics, Gynecology and Perinatology Named after V.I.Kulakov Ministry of Healthcare of the Russian Federation, Moscow, Russia.
ba0003pp312
The effect of risedronate on hypogonadal osteoporotic HIV males treated with highly active anti-retroviral therapy: a pilot study
1Department of Internal Medicine and Medical Disciplines, Sapienza Univeristy, Rome, Italy; 2Department of Experimental Medicine, Sapienza University, Rome, Italy; 3Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy; 4Department of Radiology, Sapienza University, Rome, Italy.
ba0003pp314
Preferences of patients and health care professionals for osteoporosis drug treatment: a discrete choice experiment
1Maastricht University – CAPHRI, Maastricht, The Netherlands; 2Erasmus Rotterdam University, Rotterdam, The Netherlands; 3Ghent University Hospital, Ghent, The Netherlands; 4University of Liège, Liège, Belgium; 5University of Aberdeen, Aberdeen, UK.
ba0003pp318
Perceived vs objective knowledge in patients with osteoporosis
1Dalhousie University, Halifax, Nova Scotia, Canada; 2Capital Health, Halifax, Nova Scotia, Canada.
ba0003pp319
Effects of preventive long-term treatment with strontium ranelate and zoledronic acid to ovariectomized rats on bone microstructure
1Bioquímica Investigación, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain; 2Trabeculae, Technology Based Firm, Technological Park of Galicia, Ourense, Spain; 3Traumatology and Orthopedic Surgery, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain; 4Internal Medicine, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
ba0003pp320
To decline screening for osteoporosis: a study on individual decision making, meaning and reasons for non-participation
1Department of Endocrinology, Odense University Hospital, Odense, Denmark; 2Health Services Research Unit, Lillebaelt Hospital/IRS, University of Southern Denmark, Odense, Denmark; 3Institute of Public Health, University of Southern Denmark, Odense, Denmark; 4Section Biomedical Imaging, Department of Diagnostic Radiology, University Hospital Schleswig-Holstein, Kiel, Germany.
ba0003pp323
Effect of implant to radiologic result in treating osteoporotic intertrochanteric fracture
Konyang University Hospital, Daejeon, Republic of Korea.
ba0003pp325
Undertreatment of osteoporosis: the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS)
1St. Joseph’s Healthcare, McMaster University, Hamilton, Ontario, Canada; 2Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy; 3Department of Rheumatology, University Hospital of Lille, Lille, France; 4Bridge Medical Center, Crawley, West Sussex, UK; 5Department of Rheumatology, Maastricht University, Maastricht, The Netherlands; 6Departments of Internal Medicine and Geriatrics, Gothenburg University, Göteborg, Sweden; 7Biomedical Research Institute, University Hasselt, Diepenbeek, Belgium; 8Merck & Co., Inc., Whitehouse Station, New Jersey, USA.
ba0003pp326
Baseline data of the DEVIDE-study: DEnosumab vs Intravenous Ibandronate: a 2-year retrospective head to head real life study
1Department of Endocrinology and Metabolism, Medical University, Graz, Austria; 2The Vinforce Study Group, Medical Department II, St. Vincent Hospital, Vienna, Austria.
ba0003pp327
Analysis of adequacy in prescribing calcium supplements based on the daily dairy intake in patients at risk of osteoporosis
1Servicio de Metabolismo Oseo Y Mineral, HUCA, Instituto Reina Sofia de Investigacion, Oviedo, Asturias, Spain; 2Departamento de Biología Funcional, Universidad de Oviedo, Oviedo, Asturias, Spain; 3Facultad de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain.
ba0003pp329
Prevalence of osteoporosis treatment depending on the risk evaluation of the osteoporotic fractures in patients with rheumatoid arthritis in Russia
1Research Institute for Rheumatology RAMS, Moscow, Russia; 2Regional Clinical Hospital of Vladivostok, Vladivostok, Russia; 3Medical University, ‘Kemerovo State Medical Institute’, Russian Ministry of Health, Kemerovo, Russia; 4Medical University, ‘Voronezh State Medical Academy named after Burdenko’, Voronezh, Russia; 5Medical University, ‘Ivanovo State Medical Academy’ of the Ministry of Health of the Russian Federation, Ivanovo, Russia; 6Research Experimental Institute of Rheumatology RAMS, Volgograd, Russia.
ba0003pp331
Denosumab therapy of osteoporosis in patients after solid organ transplantation and impaired renal function
Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
ba0003pp332
Comparison of efficacy teriparatide between denosumab and on hip BMD in women with severe post-menopausal osteoporosis
1UOC Endocrinologia, Ospedale S. Giovanni Calibita, Fatebenefratelli, Isola Tiberina, Rome, Italy; 2Dipartimento di Medicina dei Sistemi, Università di Tor Vergata, Rome, Italy; 3SeSMIT AFaR, Fatebenefratelli, Isola Tiberina, Rome, Italy.
ba0003pp334
A survey of oral health attitudes and practices amongst bisphosphonate users in UK
1Dental Sciences, Cardiff, UK; 2Glangwili Hospital, Carmarthen, UK.
ba0003pp335
The effect of alendronate oral jelly in the treatment of osteoporosis in clinical settings
1Okimoto Clinic, Hiroshima, Japan; 2Obase Hospial, Fukuoka, Japan; 3Sakamidorii Hospital, Hiroshima, Japan.
ba0003pp336
Monitoring of calcium intake and vitamin D saturation in Slovak postmenopausal women
15th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia; 2National Institute for Endocrinology and Diabetology, Lubochna, Slovakia; 3Osteocentrum Hospital Kosice-Saca, Kosice, Slovakia.
ba0003pp337
Patients at high risk of fragility fracture and teriparatide: report from a third level osteoporosis clinic
Section of Rheumatology, Department of Medical Science, University of Ferrara and Azienda Ospedaliero-Universitaria Sant’Anna di Cona, Ferrara, Italy.
ba0003pp338
Recommendations for osteoporosis management and fracture prevention for the frail elderly in long-term care
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; 3Department of Medicine, McGill University, Montreal, Quebec, Canada; 4Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 5Department of Medicine, University of Western Ontario, London, Ontario, Canada; 6Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada; 7Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada; 8Baycrest, Toronto, Ontario, Canada; 9Department of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada; 10School of Nursing, McMaster University, Hamilton, Ontario, Canada; 11Department of Dietetics and Human Nutrition, McGill University, Montreal, Quebec, Canada; 12Department of Nutrition and Dietetics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; 13Osteoporosis Canada, Toronto, Ontario, Canada.
ba0003pp339
Changes on bone turnover markers and bone mineral density in women with postmenopausical osteoporosis treated with denosumab
1Metabolic Bone Disease Unit, Department of Internal Medicine, Hospital Universitario Infanta Leonor, Madrid, Spain; 2Metabolic Bone Disease Unit, Department of Internal Medicine, Fundación Jiménez Díaz, Madrid, Spain; 3Investigación–Epidemiología. IIS Fundación Jiménez Díaz, Madrid, Spain.
ba0003pp341
Efficacy of Denosumab on bone metabolism after a 12-month treatment, in women with severe post-menopausal osteoporosis
1UOC Endocrinologia, Ospedale S. Giovanni Calibita, Fatebenefratelli, Isola Tiberina, Rome, Italy; 2Dipartimento di Medicina dei Sistemi, Università di Tor Vergata, Rome, Italy; 3SeSMIT AFaR, Fatebenefratelli, Isola Tiberina, Rome, Italy.
ba0003pp346
The efficacy of the treatment with intravenous ibandronate in common population.
Institute of revmatology, Na Slupi 4, Prague 2, Czech Republic.
ba0003pp347
Physical performance and risk of fall in elderly people with severe osteoporosis
1Department of Geriatrics Hospital of Patti, Patti-Messina, Italy; 2School of Medicine, University of Messina, Messina, Italy.
ba0003pp348
Bisphosphonate-associated atypical femoral fracture, effect of teriparatide
1Department of Rheumatology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium; 2Department of Radiology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
ba0003pp349
A transdermal patch delivering the PTHrP1-34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo
1Radius Health, Inc., Cambridge, Massachusetts, USA; 2CCBR, Clinical Research, Denmark; 3M Drug Delivery Systems, St. Paul, Minnesota, USA.
ba0003pp351
Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey
1Radius Health, Cambridge, Massachusetts, USA; 2Charles River Laboratories Preclinical Services Montreal, Quebec, Canada; 3School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
ba0003pp352
PTH treatment induces WNT10b expression in humans lymphoid cells
1Department of Medical Science, University of Torino, Torino, Italy; 2Cerms, Health And Science City Hospital, Torino, Italy.
ba0003pp353
Denosumab treatment in women with osteoporosis reduces hip cortical porosity
1Austin Health, University of Melbourne, Melbourne, Australia; 2Amgen, Inc., Thousand Oaks, California, USA; 3Oregon Osteoporosis Center, Portland, Oregon, USA; 4Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina; 5University of British Columbia, Vancouver, British Columbia, Canada; 6Curato Røntgen, Oslo, Norway.
ba0003pp354
Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment
1Amgen, Inc., Thousand Oaks, California, USA; 2Harvard Medical School, Boston, Massachusetts, USA; 3Harvard School of Dental Medicine, Boston, Massachusetts, USA; 4College of Physicians and Surgeons of Columbia University, New York, New York, USA; 5Regional Bone Center, Helen Hayes Hospital, New York, New York, USA.
ba0003pp355
Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone mass
1INSERM U1059, University Hospital of St Etienne, St Etienne, France; 2University of Toronto, Toronto, Ontario, Canada; 3Columbia University, New York, New York, USA; 4Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina; 5Mayo Clinic, Rochester, Minnesota, USA; 6Center of Bone Diseases, Lausanne University Hospital, Lausanne, Switzerland; 7Amgen, Inc., Thousand Oaks, California, USA.
ba0003pp356
In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate
1CHU de Quebec Research Centre, Laval University, Quebec City, Quebec, Canada; 2Bethesda Health Research Center, Bethesda, Maryland, USA; 3Amgen, Inc., Thousand Oaks, California, USA; 4Paris Descartes University, Paris, France; 5Michigan Bone and Mineral Clinic, Detroit, Michigan, USA; 6Clinical Research Center of North Texas, Denton, Texas, USA; 7VieCuri Medical Centre, Maastricht University, Maastricht, The Netherlands; 8Amgen Ltd, Cambridge, UK; 9Ovatech Solutions, London, UK; 10United Osteoporosis Centers, Gainsville, Georgia, USA.
ba0003pp357
Zoledronate reverses bone marrow adiposity in disuse osteopenic rats
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
ba0003pp358
Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study
First Medical Department, Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, Hanusch Hospital, Vienna, Austria.
ba0003pp359
Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study
1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Univ of Oxford, Oxford, UK; 2Odense Patient Data Explorative Network, University of Southern Denmark, Odense, Denmark; 3Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark; 4Department of Human Metabolism, University of Sheffield, Sheffield, UK; 5Hospital del Mar, Barcelona, Spain; 6MRC Lifecourse Epidemiology Unit, Southampton, UK; 7Research Centre for Ageing and Osteoporosis, Glostrup Hospital, Copenhagen, Denmark.
ba0003pp360
Protein malnutrition attenuates bone anabolic response to PTH in female rats
1Division of Bone Disease, Department of Internal Medicine Specialties, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 2Novartis Institutes for BioMedical Research, Basel, Switzerland.
ba0003pp361